Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kylin Therapeutics, a developer of RNAi therapeutics, has announced the expansion of its R&D efforts. The project will advance promising new RNAi cancer therapies, the company said.
Subscribe to our email newsletter
This expanded effort will be conducted at Purdue University’s Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin’s proprietary pRNAi platform.
pRNA is a discrete, RNA-based nanoparticle system. Kylin has re-engineered pRNA to induce RNA interference (RNAi). The resulting therapeutic platform is called pRNAi. This platform represents the next generation of RNAi-inducing therapeutics with superior pharmacokinetics and potency over siRNA, said Kylin.
Eric Davis, president and CEO of Kylin, said: “Our in vivo efforts have shown pRNAi to be a very potent and versatile RNA inducing platform. This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets.”